56 related articles for article (PubMed ID: 29292804)
1. Erratum: Guideline development for the management of gout: role of combination therapy with a focus on lesinurad [Corrigendum].
Drug Des Devel Ther; 2017; 11():3589-3590. PubMed ID: 29292804
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
Fleischmann R; Kerr B; Yeh LT; Suster M; Shen Z; Polvent E; Hingorani V; Quart B; Manhard K; Miner JN; Baumgartner S;
Rheumatology (Oxford); 2014 Dec; 53(12):2167-74. PubMed ID: 24509406
[TBL] [Abstract][Full Text] [Related]
3. Lesinurad: First Global Approval.
Hoy SM
Drugs; 2016 Mar; 76(4):509-16. PubMed ID: 26861027
[TBL] [Abstract][Full Text] [Related]
4. Erratum: Utility of the Morisky Medication Adherence Scale in gout: a prospective study [Corrigendum].
Patient Prefer Adherence; 2018; 12():527. PubMed ID: 29686486
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment.
Shen Z; Tieu K; Wilson D; Bucci G; Gillen M; Lee C; Kerr B
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):377-387. PubMed ID: 28074640
[TBL] [Abstract][Full Text] [Related]
6. Erratum: Fixed combination of lercanidipine and enalapril in the management of hypertension; focus on patient preference and adherence [Corrigendum].
Patient Prefer Adherence; 2013; 7():801. PubMed ID: 23976845
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and CYP Enzyme Substrates Sildenafil, Amlodipine, Tolbutamide, and Repaglinide.
Gillen M; Yang C; Wilson D; Valdez S; Lee C; Kerr B; Shen Z
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):363-376. PubMed ID: 28067999
[TBL] [Abstract][Full Text] [Related]
8. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.
Gillen M; Valdez S; Zhou D; Kerr B; Lee CA; Shen Z
Drug Des Devel Ther; 2016; 10():3555-3562. PubMed ID: 27843295
[TBL] [Abstract][Full Text] [Related]
9. Erratum: Potential Development of a Mobile Application for Gout Self-Management: What Support Do Patients Need? [Corrigendum].
Patient Prefer Adherence; 2021; 15():2647-2648. PubMed ID: 34853509
[TBL] [Abstract][Full Text] [Related]
10. A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout: Erratum.
J Clin Rheumatol; 2014 Sep; 20(6):E1. PubMed ID: 25756966
[TBL] [Abstract][Full Text] [Related]
11. Erratum: Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia [Corrigendum].
Int J Nanomedicine; 2018; 13():615. PubMed ID: 29443320
[TBL] [Abstract][Full Text] [Related]
12. Erratum: Development of an integral assessment approach of health status in patients with obstructive airway diseases: the CORONA study [Corrigendum].
Int J Chron Obstruct Pulmon Dis; 2016; 11():191. PubMed ID: 26889083
[TBL] [Abstract][Full Text] [Related]
13. Erratum: The Anæmia of Pregnancy: Corrigendum.
Gupta N
Ind Med Gaz; 1932 Nov; 67(11):658. PubMed ID: 29011034
[TBL] [Abstract][Full Text] [Related]
14. Erratum: Mercurochrome in Leprosy a Corrigendum.
Rao GR; Roy AT
Ind Med Gaz; 1932 Jul; 67(7):417. PubMed ID: 29010961
[TBL] [Abstract][Full Text] [Related]
15. Erratum: A Case for Diagnosis. (Corrigendum).
Ind Med Gaz; 1929 May; 64(5):299. PubMed ID: 29009832
[TBL] [Abstract][Full Text] [Related]
16. Erratum: The Indian Medical Year, 1928: Corrigendum.
Ind Med Gaz; 1929 Jun; 64(6):335. PubMed ID: 29009664
[TBL] [Abstract][Full Text] [Related]
17. Erratum: Polyethylenimine-based micro/nanoparticles as vaccine adjuvants [Corrigendum].
Int J Nanomedicine; 2017; 12():7239. PubMed ID: 29042772
[TBL] [Abstract][Full Text] [Related]
18. Erratum: Quantum mechanics implementation in drug-design workflows: does it really help? [Corrigendum].
Drug Des Devel Ther; 2017; 11():3205. PubMed ID: 29184390
[TBL] [Abstract][Full Text] [Related]
19. Erratum: Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease [Corrigendum].
Drug Des Devel Ther; 2015; 9():5213. PubMed ID: 26388688
[TBL] [Abstract][Full Text] [Related]
20. Erratum: Ex vivo distribution of gold nanoparticles in choroidal melanoma [Corrigendum].
Int J Nanomedicine; 2018; 13():1295. PubMed ID: 29569644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
